Received 07/07/2022 review began 09/10/2022 review ended 01/16/2023 published 02/05/2023

HIGHLIGHTS

• who: Proprotein Convertase Subtilisin/Kexin Type et al. from the Institute of Behavioral Neurosciences and Psychology, Fairfield, USA Psychiatry and Behavioral Sciences, California have published the Article: Received 07/07/2022 Review began 09/10/2022 Review ended 01/16/2023 Published 02/05/2023, in the Journal: (JOURNAL) of April/21,/2022
• what: The aim of this systematic review is to describe the mechanism of PCSK9 inhibitors and further discuss their ability to reduce CV risk in high-risk populations.
• how: The quality of the studies was evaluated using the Cochrane Collaboration . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.